Skip to content
ppharmaranks
Menu

Cabozantinib: uses, dosing, side effects & brands

Cabozantinib is a medicine sold in the U.S. under one brand. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.

By the pharmaranks editorial teamReviewed against the FDA (openFDA label, NDC Directory & Enforcement) sourcesUpdated Jul 24, 2026How we research

Key facts

Available as
Tablet
Sold as
Resniben
Prescription?
Prescription only
Generic available?
Not in our catalog

Every cabozantinib product we track (1)

Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.

Only one: Resniben.

What cabozantinib pills look like

Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.

Cabozantinib pill imprints
ImprintStrengthColourShape
XL184;20mg20 mggraycapsule
XL;6060 mgyellowoval
XL;4040 mgyellowtriangle
XL;2020 mgyellowround

Can you crush or split cabozantinib?

At least one cabozantinibproduct is labelled to be swallowed whole — crushing an extended-release tablet releases the whole day’s dose at once. Which applies depends on the form you were given.

What each cabozantinib label says about crushing, splitting and chewing

What people report to the FDA about cabozantinib

The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 3,361 reports naming cabozantinib, and the FDA flagged 91% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:

  • diarrhoea445 reports
  • fatigue299 reports
  • malignant neoplasm progression285 reports
  • nausea244 reports
  • decreased appetite227 reports
  • asthenia179 reports
  • hypertension179 reports
  • stomatitis161 reports

Read these as a signal, not a rate. A report does not mean cabozantinib caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.

Source: openFDA drug/event (FAERS), retrieved July 25, 2026.

Related calculators

Frequently asked questions

Can you take cabozantinib with other medicines?

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run cabozantinib against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

What forms does cabozantinib come in?

Across the brands we track, cabozantinib is currently marketed as tablet, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Is there a generic cabozantinib?

We do not currently list a generic-labelled cabozantinib product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.

Cite this page
APA
pharmaranks. (2026, July 24). Cabozantinib: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/cabozantinib
MLA
“Cabozantinib: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/cabozantinib.

We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.

Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.

Read the full FDA label for cabozantinib on DailyMed (NIH) ↗.